The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer
Open accessAbstract
Protein Phosphatase 2A (PP2A) is an important and ubiquitously expressed serine threonine phosphatase and regulates the function by dephosphorylating many critical cellular molecules like Akt, p53, c-Myc and β-catenin. It plays a critical role in cellular processes, such as cell proliferation, signal transduction and apoptosis. Structurally, it is multifarious as it is composed of catalytic, scaffold and regulatory subunits. The catalytic and scaffold subunits have two isoforms and the regulatory subunit has four different families containing different isoforms. The regulatory subunit is the most diverse with temporal and spatial specificity. PP2A undergoes post-translational modifications (i.e. phosphorylation and methylation), which in turn, regulates its enzymatic activity. Aberrant expression, mutations and somatic alterations of the PP2A scaffold and regulatory subunits have been observed in various human malignancies, including lung, breast, skin and colon cancer, highlighting its role as a ‘tumor suppressor’. This review is focused on the structural complexity of serine/threonine phosphatase PP2A and summarizes its expression pattern in cancer. Additionally, the PP2A interacting and regulatory proteins and substrates are also discussed. Finally, the mouse models developed to understand the biological role of PP2A subunits in an in vivo model system are also reviewed in this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, W., Arroyo, J. D., Timmons, J. C., Possemato, R., & Hahn, W. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1103 · Cited by 159
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks
Olsen, J. V., Blagoev, B., Gnad, F., Macek, B., Kumar, C., Mortensen, P., & Mann, M. (2006) · Cell · doi:10.1016/j.cell.2006.09.026 · Cited by 3,499
Janssens, V., & Goris, J. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3530417 · Cited by 1,902
Protein Tyrosine Phosphatases in the Human Genome
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Herman, J. G., Merlo, A. U., Mao, L., Lapidus, R. G., Issa, J. J., Davidson, N. E., Sidransky, D., & Baylin, S. B. (1995) · PubMed · Cited by 1,341
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Regulation of protein kinase cascades by protein phosphatase 2A
Millward, T. A., Zolnierowicz, S., & Hemmings, B. A. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01375-4 · Cited by 793
Cited by
Current treatment strategies for inhibiting mTOR in cancer
Chiarini, F., Evangelisti, C., McCubrey, J. A., & Martelli, A. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.004 · Cited by 275
Huang, K.-L., Jee, D., Stein, C. B., Elrod, N. D., Henriques, T., Mascibroda, L. G., Baillat, D., Russell, W. K., Adelman, K., & Wagner, E. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.08.016 · Cited by 184
“The canonical mode for PP2A binding to target proteins is through differential association of the PR65/PP2Ac catalytic heterodimer with members of a broad family of PP2A ‘B’ regulatory subunits (Seshacharyulu et al., 2013; Shi, 2009).”
BackgroundREDD1 enhances protein phosphatase 2A-mediated dephosphorylation of Akt to repress mTORC1 signaling
Dennis, M. D., Coleman, C. S., Berg, A., Jefferson, L. S., & Kimball, S. R. (2014) · Science Signaling · doi:10.1126/scisignal.2005103 · Cited by 159
Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs)
Chen, P.-H., Hu, Z., An, E., Okeke, I., Zheng, S., Luo, X., Gong, A., Jaime-Figueroa, S., & Crews, C. M. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00693 · Cited by 130
Di Conza, G., Trusso Cafarello, S., Loroch, S., Mennerich, D., Deschoemaeker, S., Di Matteo, M., Ehling, M., Gevaert, K., Prenen, H., Zahedi, R. P., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.051 · Cited by 119
Hu, Z., Chen, P.-H., Li, W., Douglas, T., Hines, J., Liu, Y., & Crews, C. M. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11706 · Cited by 98
Loveday, C., Tatton-Brown, K., Clarke, M., Westwood, I., Renwick, A., Ramsay, E., Nemeth, A., Campbell, J., Joss, S., Gardner, M., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv182 · Cited by 87
The role of CIP2A in cancer: A review and update
Soofiyani, S. R., Hejazi, M. S., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.146 · Cited by 72
Hein, A. L., Seshacharyulu, P., Rachagani, S., Sheinin, Y. M., Ouellette, M. M., Ponnusamy, M. P., Mumby, M. C., Batra, S. K., & Yan, Y. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2119 · Cited by 66
Self-citationInactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors
O’Connor, C. M., Leonard, D., Wiredja, D., Avelar, R. A., Wang, Z., Schlatzer, D., Bryson, B., Tokala, E., Taylor, S. E., Upadhyay, A., et al. (2020) · Oncogene · doi:10.1038/s41388-019-1012-2 · Cited by 48
Zhuang, Q., Zhou, T., He, C., Zhang, S., Qiu, Y., Luo, B., Zhao, R., Liu, H., Lin, Y., & Lin, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0341-z · Cited by 38
Nardi, F., Lipina, C., Magill, D., Hage Hassan, R., Hajduch, E., Gray, A., & Hundal, H. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092255 · Cited by 36
PH domain-mediated autoinhibition and oncogenic activation of Akt
Bae, H., Viennet, T., Park, E., Chu, N., Salguero, A., Eck, M. J., Arthanari, H., & Cole, P. A. (2022) · eLife · doi:10.7554/elife.80148 · Cited by 31
PPP2R5A: A multirole protein phosphatase subunit in regulating cancer development
Mao, Z., Liu, C., Lin, X., Sun, B., & Su, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.024 · Cited by 30
Virus–Host Interactions in Retrovirus Integration
Engelman, A. N., & Maertens, G. N. (2018) · Retrovirus-Cell Interactions · doi:10.1016/b978-0-12-811185-7.00004-2 · Cited by 12
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
Metadata
- Authors
- Seshacharyulu, P., Pandey, P., Datta, K., & Batra, S. K.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 335
- Issue
- 1
- Pages
- 9-18
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W1992060900
- Cited by
- 481
- References
- 110
- FWCI
- 15.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.